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Available online 14 March 2016Recent issues regarding efﬁcacy of inﬂuenza vaccines have re-emphasized the need of new approaches to face
this major public health issue. In a phase 1–2 clinical trial, healthy adults received one intramuscular dose of a
seasonal inﬂuenza plant-based quadrivalent virus-like particle (QVLP) vaccine or placebo. The hemagglutination
inhibition (HI) titersmet all the European licensure criteria for the type A inﬂuenza strains at the 3 μg/strain dose
and for all four strains at the higher dosages 21 days after immunization. HighHI titers weremaintained formost
of the strains 6 months after vaccination. QVLP vaccine induced a substantial and sustained increase of
hemagglutinin-speciﬁc polyfunctional CD4 T cells, mainly transitional memory and TEMRA effector IFN-γ+
CD4 T cells. A T cells cross-reactive response was also observed against A/Hong-Kong/1/1968 H3N2 and
B/Massachusetts/2/2012. Plant-based QVLP offers an attractive alternative manufacturing method for
producing effective and HA-strain matching seasonal inﬂuenza vaccines.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Inﬂuenza A viruses are a major public health threat and, in the USA
alone, seasonal epidemics account for N200.000 hospitalizations and
N30.000 deaths annually [1]. Inﬂuenza B viruses can also cause seasonal
epidemics in adults every two to four years. Based on data across four
seasons, the clinical symptoms and hospital admission rates are similar
in subjects infectedwith either inﬂuenza A or B [2]. Vaccination remains
the most cost-effective means to control the health burden attributable
to inﬂuenza. Seasonal inﬂuenza vaccines have historically included
three strains: two inﬂuenza A strains and only one inﬂuenza B strain.
As two antigenically-distinct inﬂuenza B lineages (B/Victoria and B/
Yamagata) have co-circulated in North America since 2000, there have
been frequent mismatches leading to a reduced vaccine effectiveness
[3,4]. Indeed, split-virion vaccination against one B lineage provides
little-to-no cross-protection against the alternate lineage [5,6]. It has
been estimated that inclusion of both Victoria and Yamagata lineages
in a quadrivalent inactivated vaccine (QIV) between 1999 and 2009
could have resulted in a major and signiﬁcant reduction of the public
health burden of inﬂuenza infections [7]. For the 2012–2013 Northernu 600, Québec, QC, Canada, G1V
. This is an open access article underhemisphere inﬂuenza season, the World Health Organization (WHO)
recommended the inclusion of a B strain from each lineage in the
seasonal vaccine for the ﬁrst time. Since that time, several different
QIV formulations have been shown to be immunogenic for all four vac-
cine strains in children as young as 6 months and in adults [8–11]. Al-
most all of the currently used inﬂuenza vaccines have been designed
to induce antibodies (Abs) against the viral surface glycoproteins, hem-
agglutinin (HA) in particular. These Abs, detected by HA inhibition (HI)
assay, are thought to prevent viral attachment to host cells. The post-
vaccination serum HI titer has been widely used as a surrogate marker
for vaccine efﬁcacy compliant with European Medicines Agency
(EMEA) and Food and Drug Administration (FDA) guidelines. However
there is mounting evidence that T cell-mediated immunity (CMI) plays
an important role in controlling inﬂuenza. Studies in both animal
models and humans demonstrate that protection can occur in absence
or with very low level of Abs and HI titers, pointing out the role of the
CMI in the control of the virus replication and the resolution of the dis-
ease. Moreover, CMI has recently been demonstrated to play a pivotal
role in cross-protection against drifted and heterologous strains
[12–15]. Although most of the work on CMI to date has focused on the
conserved epitopes of internal inﬂuenza proteins like nucleoprotein
(NP) and M protein, recent data demonstrate that the inﬂuenza HA
molecule also contains class I- and class II-restricted epitopes and that
HA-speciﬁc T cell responses can be detected after inﬂuenza infection
or vaccination [16–20].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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proved to be immunogenic in both animal models and humans
[21–24]. Plant-based VLP vaccines have the potential to address several
of the limitations of currently licensed products including response time
and scalability in the event of a pandemic. Furthermore, the plant-based
vaccines target wild-type HA sequences in contrast to inﬂuenza strains
grown in eggs or tissue culture that may have mutated for optimal
growth, possibly compromising the effectiveness of the vaccine [25]. Fi-
nally, some highly-pathogenic avian inﬂuenza (HPAI) strains like H5N1
replicate very poorly in eggs thereby reducing vaccine production
capacity.
Herein we described the results from a phase 1–2 randomized
clinical trial conducted to assess the safety, tolerability, and immu-
nogenicity of a non-adjuvanted plant-derived quadrivalent VLP in-
ﬂuenza (QVLP) vaccine in healthy adults. This QVLP vaccine was
well-tolerated and elicited sustained, cross-reactive humoral and
cell-mediated immune responses.
2. Methods
2.1. Production of plant-derived HA VLP inﬂuenza vaccine
The QVLP vaccine was produced in Nicotiana benthamiana using the
Agrobacterium inﬁltration-based transient expression plateform as
previously described [21,26]. The HA protein in the VLPs were
based on HA sequences of A/California/07/2009 H1N1 (A/H1N1 Cal),
A/Victoria/361/11 H3N2 (A/H3N2 Vic), B/Brisbane/60/08 (B/Bris,
Victoria lineage) or B/Wisconsin/1/10 (B/Wis, Yamagata lineage)
inﬂuenza strains according to the recommendations of the World
Health Organization for the 2013–2014 North Hemisphere inﬂuenza
season. Drug Substances for each strainwere combined into a quadriva-
lent Drug Product. Final doseswere based onHA content. Each dosewas
administered in a volume of 0.5 ml in the deltoid muscle of the non-
dominant arm.
2.2. Study design and objectives
Eligible male and female subjects between 18 and 49 years of age
were enrolled for this phase 1–2 randomized, double-blind, placebo-
controlled, dose-ranging clinical trial (NCT01991587 at ClinicalTrials.
gov) conducted in the United States between May 2013 and February
2014. The study was carried out in accordance with the Declaration of
Helsinki and the principles of Good Clinical Practices andwas approved
by the site's Ethics Review Board and by the Center for Biologics Evalu-
ation and Research (CBER). Criteria of exclusion were detailed in the
Suppl. Table 1. The primary objectiveswere to evaluate safety and toler-
ability of a single dose of the QVLP vaccine administered intramuscular-
ly (IM) aswell as the immunogenicity of the vaccine asmeasured by the
HI antibody assay. Secondary and exploratory objectives focused on
cross-reactivity of the HI antibody response, neutralisation of homolo-
gous and heterologous strains in the microneutralization (MN) assay
and CD4 T cell responses against homologous and heterologous strains.
Antibody responses (e.g.: IgG, IgE) to plant glycans were also measured
by the ImmunoCap test (Pharmacia & Upjohn, Uppsala, Sweden).
2.2.1. Study procedures
The Phase 1 portion of this study used dose escalation with slow en-
rolment (staggered cohorts) for the 3 dose levels (3 μg, 9 μg, and 15 μg
VLP per strain) with a placebo-controlled group. In the ﬁrst Cohort, 13
subjects were randomized to receive the lowest QVLP dose (3 μg of
each strain: n = 10) or placebo (phosphate buffer saline pH 7.4:
100 mM NaKPO4, 150 mM NaCl, 0.01% Tween-80, n = 3). Once the 7-
day safety data had been reviewed by the Data and Safety Monitoring
Board (DSMB) the second cohort of 13 subjects was randomized to re-
ceive themedium dose of QVLP (9 μg of each strain: n=10) or placebo
(n = 3). Again, DSMB review of the 7-day safety data permittedrandomization of the third cohort to receive either the high dose of
QVLP (15 μg of each strain, n=10) or placebo (n=4). Upon satisfacto-
ry DSMB review the 7-day safety data for the third cohort, the Phase 2
portion of the study was initiated during which 80 subjects were
randomised (1:1:1:1) to receive one of three QVLP vaccine doses or
placebo. Blood samples for hematology and biochemistry and urine
(routine & microscopic) were collected at screening, D3 and D201.
Serum pregnancy tests (for female subjects) were performed at screen-
ing, D0, D21 and D201. Serum samples were obtained at D0, D21 and
D201for HI and MN assays and measurement of antibodies against
plant glycans. Anti-coagulated (EDTA) whole blood samples were col-
lected in a subset of 10 subjects per group for analysis of T cell responses
at D0, D21 and D201.
2.2.2. Safety/reactogenicity assessments
Subjects were observed for 30 min after vaccination for immediate
reactions and were provided with diary cards to record solicited local
or systemic reactions that occurred up to seven days after vaccination.
Solicited local reactions included pain, swelling and redness (or erythe-
ma). Solicited systemic reactions included fever (≥38 °C), headache,
muscle aches, joint aches, fatigue, chills, feeling of general discomfort
or uneasiness and swelling (axilla, groin, neck, and/or chest). The sever-
ity of reported symptomswas assessed asmild, moderate or severe. Un-
solicited adverse events (AEs) were collected from D0 through D21. All
serious adverse events (SAEs), new onset of chronic disease (NOCD)
and AEs leading to study withdrawal were collected throughout the
study. Causality of all unsolicited AEs/SAEs/NOCDs was evaluated by
the investigator and reported as deﬁnitely not related, probably not re-
lated, possibly related, probably related or deﬁnitely related.
2.2.3. HI assay
The HI assay was performed on serum samples as previously de-
scribed according to WHO recommendations [23,27]. The homologous
antigens (Ag) tested were A/H1N1 Cal propagated in Madin-Darby
(Southern Research Institute), A/Texas/50/2012 H3N2 (A/H3N2 Tx,
NYMCX-223 A, National Institute for Biological Standards and Control,
NIBSC) a virus antigenically like the cell-propagated virus A/H3N2 Vic,
B/Bris (NYMC BX-35, NIBSC) and B/Wis (NIBSC #12/110). The heterolo-
gous Ag tested were A/Brisbane/59/2007 H1N1 (A/H1N1 Bris, IVR-148,
NIBSC #08/100), A/Uruguay/716/2007 H3N2 (A/H3N2 Uru, NYMC-
175C, NIBSC #08/278), B/Malaysia/2506/2004 (B/Mal, NIBSC #08/184)
and B/Massachusetts/02/2012 (B/Mass, NIBSC #13/152). Serum titers
are expressed as the reciprocal of the highest dilution that showed
complete inhibition of hemagglutination. Although some controversy
subsists, HI titer ≥1:40 remains the reference standard indicative of
seroprotection [28–30]. Seroconversion rate (SCR), seroprotection rate
(SPR) and geometric mean fold rise (GMFR) were deﬁned according
to regulatory criteria [31] and were compared to the European Agency
for the Evaluation of Medicinal Products' CHMP criteria i.e. SCR ≥ 40%,
SPR ≥ 70%, GMFR ≥ 2.5 for healthy adults.
2.2.4. MN assay
MN antibody titers against the homologous strains A/H1N1 Cal, A/
H3N2 Vic, B/Bris, B/Wis and the heterologous strain B/Mass were mea-
sured in serum at D0 and D21 according to theWorld Health Organisa-
tion guideline for the serologic diagnosis of inﬂuenza [27]. MN titers are
expressed as the reciprocal of the highest dilution that showed com-
plete neutralization of input virus. Sera that tested negative at a dilution
of 1:10 were assigned a titer of 5 for statistical analysis. Samples were
analyzed in duplicates and repeats were performed when acceptance
criteria for the assay were not met.
2.2.5. Ex vivo T cell re-stimulation assay
Peripheral blood mononuclear cells (PBMCs) were collected at D0,
D21 and D201 after vaccination. Cells were prepared and cryopreserved
in liquid nitrogen until quickly thawed and prepared for the assays as
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VLP (homologous stimulations) for 20 h, or for 6 h with 2.5 μg/ml of
peptide pool consisting in 15-mer peptides overlapping by 11 amino
acids spanning the complete B/Mass or A/Hong-Kong/1/1968 H3N2
(A/H3N2 HK) HA proteins (heterologous stimulations, GenScript,
Piscataway, NJ). A 6 h stimulationwith a control peptide pool containing
32 peptides, 8–12 amino acids in length with sequences derived from
the human Cytomegalovirus, Epstein-Barr and inﬂuenza viruses
(CEF, 1 μg/ml, AnaSpec, Fremont, CA) or the staphylococcal enterotoxin
B (SEB, 0.25 μg/ml, Toxin Technology, Sarasota, FL) as well as
unstimulated (exposed to VLP or peptide pool vehicles') cells were in-
cluded as a positives and negative controls respectively. Anti-human
CD107a antibody (clone H4A3, Biolegend, San Diego, CA) was added
at the beginning of the stimulations as recommended by Betts and
Koup [32]. Expression of CD107a is associated with degranulation and
serves as a functional marker for cell-mediated cytotoxicity. Five hours
before the end of these incubations, 5 μg/ml of monensin and brefeldin
A (Golgi blockers, BD Biosciences, Mississauga, ON) were added to the
wells to inhibit protein secretion. Following ex vivo stimulation, cells
were stained with LIVE/DEAD ﬁxable Aqua Dead cell stain (Invitrogen),
anti-human CD16/CD56-Brilliant Violet (clones 3G8 and HCD56
respectively, Biolegend), anti-human CD14-V500 (clone M5E2, BD
Biosciences), anti-human CD3-V450 (clone SP34–2, BD Horizon, BD
Biosciences), CD4-phycoerythrin-TexasRed (clone SFCI2T4D11,
Beckman Coulter, Mississauga, ON), CD8-eFluor650 NC (clone RPA-
T8, eBioscience, San Diego, CA), CD45RA-allophycocyanin-Cyanine
7 (clone HI100, BD Pharmingen), CD27-Brilliant Violet 605 and
CCR7-phycoerythrin-Cyanine 7 (clone O323 and G043H7 respectively,
Biolegend, San Diego, CA) for 30 min at 4 °C in the dark. Cells were
washed twice with cold phosphate-buffered saline (PBS) and ﬁxed with
Cytoﬁx/Cytoperm (BD Biosciences) solution according manufacturer's
instruction followed by 3 washes with Perm/Wash buffer (BD Biosci-
ences). Intracellular cytokines were detected by staining with anti-
human IFN-γ-ﬂuorescein isothiocyanate (clone B27, BD Pharmingen),
IL-2-Alexa700 (MQ1-17H12, Biolegend) and TNF-α-allophycocyanin
(clone 6401.1111, BD Biosciences) in the Perm/Wash buffer for 30 min
at 4 °C in the dark. Cells were then washed and re-suspended in PBS
supplemented with 2% hiFBS +2 mM EDTA and kept at 4 °C until data
acquisition (within 6 h) on BD LSR II ﬂow cytometer (BD, Franklin
Lakes, NJ). Approximately 3 × 105 lymphocytes were acquired for eachTable 1
Summary of demographics and baseline characteristics (safety population).
Characteristic Placebo (N= 30) 3 μg VLP vaccine (N= 30)
Sex, n (%)
Female 16 (53.3) 15 (50.0)
Male 14 (46.7) 15 (50.0)
Race, n (%)
White or Caucasian 24 (80.0) 19 (63.3)
Black or African American 6 (20.0) 11 (36.7)
Ethnicity, n (%)
Hispanic or Latino 24 (80.0) 21 (70.0)
Not Hispanic or Latino 6 (20.0) 9 (30.0)
Age (years)
Mean (SD) 34.4 (9.04) 33.5 (10.58)
Range 18–49 19–49
BMI (kg/m2)
Mean (SD) 25.42 (3.544) 24.87 (4.069)
Range 19.8–31.7 18.4–31.1
Inﬂuenza Immunization History, n (%)
Yes 1 (3.3) 1 (3.3)
No 29 (96.7) 29 (96.7)
a p-Value for the difference of the number of subjects between treatment groups and two le
b p-Value for the difference of the number of subjects between treatment groups and Cauca
c p-Value for the difference between treatment groups from an analysis of variance with tre
d p-Value for the difference of the number of subjects between treatment groups and inﬂuesample and data were analyzed using FlowJo™ (Tree Star, OR) and
SPICE (http://exon.niaid.nih.gov/spice) software. The gating strategy is
detailed in Suppl. Fig. 3. The total cell viability was always N85% and anal-
yses were only performed on AQUA dye-negative, live cells. SPICE-based
functional analysis was performed on background-subtracted values
from non-stimulated samples.2.2.6. Antibodies to plant glycans associated with hypersensitivity/allergy
reactions
In order to determine if QVLP vaccine can induce antibodies to plant-
speciﬁc β(1–2) xylose and α(1–3) fucose carbohydrates found on the
vaccine, serum IgE levels to plant-speciﬁc glycans were evaluated
using samples collected at D0 and D21 as reported previously [33].
Brieﬂy, the ImmunoCAP bromelain assays (Pharmacia & Upjohn,
Uppsala, Sweden) was used to measure IgE directed against MUXF3, a
carbohydrate motif found on many plant allergens that can trigger his-
tamine release bymast cells and basophils in vitro. Positive responses in
the ImmunoCAP assay (graded 0–4) are correlated with clinically-
apparent allergic responses [34–36].2.3. Statistical analysis
All safety endpoints were summarized by treatment groups using
descriptive statistics. The GMFR and the geometric mean titer (GMT)
were compared using analysis of variance (ANOVA) followed by a
Tukey-Kramer post-hoc test for pairwise comparison inside each sam-
pling day while the Sidak's multiple comparison test was used to com-
pare the response at different time for a same vaccine dose or placebo.
The SCR and SPR were compared using the Fisher's exact test. Two-
group comparisons between CMI responses in placebo and 15 μg QVLP
groups were assessed by parametric unpaired t tests or non-
parametric Mann-Whitney test when data did not meet the condition
for application of a parametric test. Multiple comparisons between the
CD4 T cell functional signatures of placebo and 15 μg QVLP groups
were assessed by multiple t tests using the Holm-Sidak method to cor-
rect for multiple comparisons. The statistical analyses were performed
using SAS® software (version 9.2) and GraphPad Prism (version 6.03,
GraphPad Software, La Jolla, CA).9 μg VLP vaccine (N= 30) 15 μg VLP vaccine (N= 30) p-Value
20 (66.7) 12 (40.0) 0.2264a
10 (33.3) 18 (60.0)
22 (73.3) 24 (80.0) 0.4195b
8 (26.7) 6 (20.0)
21 (70.0) 25 (83.3) 0.5282a
9 (30.0) 5 (16.7)
34.9 (8.32) 31.9 (9.67) 0.6279c
21–49 19–48
25.09 (3.795) 26.75 (3.294) 0.2000c
18.9–32.1 19.4–31.1
2 (6.7) 3 (10.0) 0.8340d
28 (93.3) 27 (90.0)
vels of the demographic variable by Fisher's exact test.
sian vs other races by Fisher's exact test.
atment group as factor.
nza immunized vs not immunized by Fisher's exact test.
Fig. 1. Subject disposition from screening to day 201 visit.
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Gender was well-distributed between the groups except in the 9 μg
QVLP group that had a higher proportion of female subjects (Table 1).
Greater than half of the subjects (N63.3%) for all vaccine groups were
white or Caucasian and Hispanic or Latino in origin; the remaining sub-
jects were black or African American. The mean age and body mass
index (BMI) were similar among all groups. The previous inﬂuenza vac-
cination rate was rather low in all groups (≤10%) considering the rec-
ommendation for annual inﬂuenza vaccination in the United States. As
shown in Fig. 1, 120 subjects were randomized and received either
QVLP vaccine or placebo. Overall, 96.7% of subjects completed the
study through D21 and 85.8% through D201.3.1. Safety
The QVLP vaccine was well-tolerated at each dose level (Table 2).
The overall reactogenicity increased with increasing dose but did not
achieve statistical signiﬁcance. Pain at the injection site in the 7 days
post-vaccination was reported the most common local solicited AE oc-
curring in 50% of the 15 μg dose recipients and 36.7% in the 3 μg and
9 μg dose groups (versus 13.3% in the placebo group) (Table 2). Differ-
ences in the incidence of local symptoms were not statistically signiﬁ-
cant between the active dose groups, except for pain in the 15 μg dose
group compared to placebo (p=0.0048). Except for one case of severe
fatigue and headache in the 15 μg group and one case of severe head-
ache in the placebo group, the majority of systemic reactions were
mild and of short duration across all vaccine doses and placebo. Head-
ache was the most common systemic AE and was similar for all QVLP
doses (3 μg = 13.3%, 9 μg = 13.3% and 15 μg = 23.3%) and placebo
(23.4%). Symptoms of mild or moderate fatigue, muscle aches, and feel-
ings of general discomfort or uneasiness were experienced in ≤10% of
QVLP vaccinated subjects andwere reported at a similar rate by the pla-
cebo group. During the 21 days after vaccination, there were no statisti-
cally signiﬁcant differences in the rates of unsolicited AE between
groups (4 in each of the 3 and 9 μg groups, 5 in the 15 μg group and 6in the placebo group). There was no SAEs or new onset of chronic dis-
ease (NOCD) during this study.
3.1.1. Immunization with QVLP does not induce allergic symptoms or IgE
responses
Given the particular nature of this vaccine, we have carefully consid-
ered the potential for allergic reactions from the outset. To date, more
than 1000 people have received 1 or 2 doses of a plant–derived VLP vac-
cine without the induction or worsening of clinical allergies or the de-
velopment of pathologic IgE responses [33]. No subject in any group
reported either worsening or induction of allergic symptoms following
QVLP vaccination. Overall, only 2 subjects had low-positive tests in the
bromelain assay: one in the highest dose QVLP group prior to immuni-
zation and one in the placebo group post-vaccination (Table 3). It is
noteworthy that the low titer to plant-origin carbohydrate motifs anti-
MUXF3 IgE actually disappeared following vaccination in the subject
who received 15 μg/strain QVLP. These observations likely reﬂect back-
ground (environmental) exposures to plant carbohydrates.
3.2. Antibody response
3.2.1. QVLP vaccine elicited a sustained HI antibody response
The HI titers against the four homologous strains increased as com-
pared to baseline (D0) values 21 days after vaccination with the VLP
vaccine. This increasewas statistically signiﬁcant for all the homologous
strains at each dose of vaccine with the exception of titers against the
two B strains in subject who received 3 μg of VLP vaccine (data not
shown). Therewas no signiﬁcant increase in HI antibody titer in the pla-
cebo group. Twenty-one days after immunization, GMT, SPR, SCR and
GMFR in vaccinated subjects were signiﬁcantly higher than the placebo
group for the four homologous strains regardless of the vaccine dose
(Figs. 2 and 3) with the exceptions of HI titers against B/Bris and SCR
for B/Bris and B/Wis in the 3 μg group (Fig. 3). A small vaccine-dose ef-
fect was observed, particularly for the two B strains (Fig. 3). The SPR for
B/Wis in the 15 μg groupwas signiﬁcantly higher than in the 3 μg group
(Fig. 3B). In addition, GMFR for B/Bris and B/Wis and SCR for B/Bris were
signiﬁcantly lower in subjects who received the 3 μg dose compared to
Table 2
Incidence of local and systemic solicited signs and symptoms through day 7 by severity (safety population).
Placebo (N= 30) 3 μg VLP vaccine (N= 30) 9 μg VLP vaccine (N= 30) 15 μg VLP vaccine (N= 30)
n (%) n (%) n (%) n (%)
Subjects with at least one local or systemic solicited
signs or symptoms
11 (36.7) 14 (46.7) 14 (46.7) 18 (60.0)
Mild 8 (26.7) 12 (40.0) 11 (36.7) 14 (46.7)
Moderate 2 (6.7) 2 (6.7) 3 (10.0) 3 (10.0)
Severe 1 (3.3) 0 0 1 (3.3)
Solicited local signs
Pain at injection site 4 (13.3) 11 (36.7) 11 (36.7) 15 (50.0)
Mild 4 (13.3) 10 (33.3) 10 (33.3) 14 (46.7)
Moderate 0 1 (3.3) 1 (3.3) 1 (3.3)
Severe 0 0 0 0
Swelling at injection site 2 (6.7) 0 2 (6.7) 2 (6.7)
Mild 2 (6.7) 0 1 (3.3) 1 (3.3)
Moderate 0 0 1 (3.3) 1 (3.3)
Severe 0 0 0 0
Solicited systemic symptoms
Headache 7 (23.3) 4 (13.3) 4 (13.3) 7 (23.3)
Mild 6 (20.0) 3 (10.0) 3 (10.0) 6 (20.0)
Moderate 1 (3.3) 1 (3.3) 1 (3.3) 0
Severe 0 0 0 1 (3.3)
Muscle aches 3 (10.0) 0 4 (13.3) 5 (16.7)
Mild 3 (10.0) 0 3 (10.0) 3 (10.0)
Moderate 0 0 1 (3.3) 2 (6.7)
Severe 0 0 0 0
Joint aches 2 (6.7) 0 0 4 (13.3)
Mild 2 (6.7) 0 0 1 (3.3)
Moderate 0 0 0 3 (10.0)
Severe 0 0 0 0
Fatigue 5 (16.7) 1 (3.3) 4 (13.3) 5 (16.7)
Mild 3 (10.0) 1 (3.3) 2 (6.7) 2 (6.7)
Moderate 1 (3.3) 0 2 (6.7) 2 (6.7)
Severe 1 (3.3) 0 0 1 (3.3)
Chills 1 (3.3) 1 (3.3) 2 (6.7) 2 (6.7)
Mild 1 (3.3) 1 (3.3) 1 (3.3) 1 (3.3)
Moderate 0 0 1 (3.3) 1 (3.3)
Severe 0 0 0 0
Feelings of general discomfort or uneasiness 4 (13.3) 1 (3.3) 3 (10.0) 4 (13.3)
Mild 2 (6.7) 1 (3.3) 3 (10.0) 3 (10.0)
Moderate 2 (6.7) 0 0 1 (3.3)
Severe 0 0 0 0
Swelling in the axilla 0 0 1 (3.3) 0
Mild 0 0 1 (3.3) 0
Moderate 0 0 0 0
Severe 0 0 0 0
Swelling in the neck 1 (3.3) 0 0 1 (3.3)
Mild 1 (3.3) 0 0 1 (3.3)
Moderate 0 0 0 0
Severe 0 0 0 0
Table 3
IgE responses to bromelain glycans.
Group Number of subjects with
IgEs ≥ grade 1 to bromelain
at screening
Number of subjects that
showed an IgE increase
21 days after vaccination
3 μg QVLP vaccine
(n= 29)
0% (0/29) 0% (0/29)
9 μg QVLP vaccine
(n= 30)
0% (0/30) 0% (0/30)
15 μg QVLP vaccine
(n= 27)
3.7% (1/27) 0% (0/27)
Placebo (n= 30) 0% (0/30) 3.3% (1/30)
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cantly higher than placebo (Fig. 3C & D). The antibody response elic-
ited by the 9 μg and 15 μg doses met all the CHMP criteria for the four
homologous strains 21 days after vaccination (Figs. 2 and 3). SCR var-
ied from 42.3 to 59.3%, SPR from 74.1.0 to 96.2% and GMFR from 3.8
to 8.0 depending on strain and dose received. All the CHMP criteria
were also met for the inﬂuenza A strains in the 3 μg group but gener-
ally fell short for the B strains: only SPR for B/Wis (72.4%) met the
criterion.
HI titers, SPR, SCR and GMFR remained signiﬁcantly higher than the
placebo group six months (D201) after immunization for the two A
strains with the exception of HI titer, SPR and GMFR for A/H1N1Cal in
the 3 μg group and GMFR for A/H1N1Cal in the 15 μg group (Fig. 2B &
D). SPR and GMFR of the 9 μg and 15 μg groups still met the CHMP
criteria for the two inﬂuenza A strains at D201. These same criteria
were also met by the antibody response against A/H3N2 Vic at D201
evenwith the lowest dose (3 μg) of VLP vaccine. In contrast, the humor-
al response against the two B strains decreased substantially between
D21 andD201 (Fig. 3). TheGMT, SPR, SCR andGMFR for B/Wiswere sig-
niﬁcantly lower at D201 than 21 days after immunization for all the vac-
cine doses tested. For the B/Bris, response differences reached statisticalsigniﬁcance for SPR in the 9 μg group, SCR in the 9 μg and 15 μg groups as
well as for GMFR at all vaccine doses tested. However, it is important to
note that HI titers and SPR for B/Wis in the 15 μg group and GMFR for B/
Bris in the 9 μg and 15 μg groups as well as GMFR for B/Wis in the 9 μg
group remained signiﬁcantly higher than placebo six months after vac-
cination (Fig. 3).
Fig. 2. Serum HI antibody response against the two homologous inﬂuenza A strains 21 and 201 days after vaccination with 3 μg, 9 μg and 15 μg of the plant-derived quadrivalent VLP
vaccine. A) Geometric mean titer (GMT), B) Percent of seroconversion rate (SPR), C) Percent of seroconversion rate (SCR) and D) Geometric mean fold increase ratio (GMFR). The
dotted lines mark the values of the CHMP criteria for licensure. The different letters indicate statistically signiﬁcant differences (p ≤ 0.05) between vaccine groups and placebo at D21
(lower case) and at D201 (upper case).
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Cross-reactive HI responsesweremeasured against heterologous in-
ﬂuenza strains 21 days after the vaccination. HI titers, SPR, SCR and
GMFR for A/H3N2 Uru and B/Mass in the QVLP subjects were signiﬁ-
cantly higher than placebo at all vaccine doses with the exception of
B/Mass titers in the 3 μg group (Figs. 4 and 5). The strong heterologous
response against A/H3N2 Uru was maintained at D201 (Fig. 4) while
only SCR and GMFR for B/Mass in the 9 μg and 15 μg groups remainedhigher than placebo (Fig. 5). Although of lower magnitude, cross-
reactive responses were also detected against A/H1N1 Bris and B/Mal
(Figs. 4 and 5). In particular, the HI titers, SPR, SCR and GMFR for B/
Mal were signiﬁcantly higher in the 15 μg QVLP recipients than the pla-
cebo 21 days after immunization (Fig. 5). HI titersmet CHMP criteria for
SPR (85.2–92.3%), SCR (55.6–61.5%) and GMFR (4.7–5.8) for B/Mass in
the 9 and the 15 μg groups respectively. Similar results were observed
for A/H3N2 Uru to which 55.6–50.0% of the 9 and 15 μg QVLP recipients
Fig. 3. Serum HI antibody response against the two homologous inﬂuenza B strains 21 and 201 days after vaccination with 3 μg, 9 μg and 15 μg of the plant-derived quadrivalent VLP
vaccine. A) Geometric Mean titer (GMT), B) Percent of seroconversion rate (SPR), C) Percent of seroconversion rate (SCR) and D) Geometric mean fold increase ratio (GMFR). The
dotted lines mark the values of the CHMP criteria for licensure. The different letters indicate statistically signiﬁcant differences (p ≤ 0.05) between vaccine groups and Placebo at D21
(lower case) and at D201 (upper case). Asterisks inserted inside the D201 bars indicate statistically signiﬁcant differences between the response at D21 and D201 for each vaccine
dose (*p ≤ 0.05, **p ≤ 0.01). Hash signs indicate statistically signiﬁcant differences between vaccine doses (#p ≤ 0.05, ##p ≤ 0.01) for each time point.
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for A/H3N2 Uru at D21 reached 66.7–61.5% in the two high QVLP dose
groups.
3.3. Neutralizing antibody response
The MN analyses were assessed 21 days post-vaccination
against homologous inﬂuenza. Pearson's average correlationcoefﬁcient between the log-transformed HI and MN titers for the
3 QVLP doses were 0.8260, 0.8888, 0.8847 and 0.8451 for A/H1N1
Cal, A/H3N2 Vic, B/Bris and B/Wis respectively (all p b 0.0001).
MN antibody titers increased with increasing vaccine dosages al-
though not achieving statistical signiﬁcance (data not shown).
MN SCR, deﬁned as 4-fold increase of baseline MN titer, obtained
at each dose and for each strain were also quite similar to the HI re-
sults (data not shown). All doses tested achieved MN SCR N40% for
Fig. 4. SerumHI antibody response against two heterologous inﬂuenza A strains 21 and 201 days after vaccination with 3 μg, 9 μg and 15 μg of the plant-derived quadrivalent VLP vaccine.
A)GeometricMean titer (GMT), B) Percent of seroconversion rate (SPR), C) Percent of seroconversion rate (SCR) andD)Geometricmean fold increase ratio (GMFR). The dotted linesmark
the values of the CHMP criteria for licensure. The different letters indicate statistically signiﬁcant differences (p ≤ 0.05) between vaccine groups and Placebo at D21 (lower case) and at
D201 (upper case). Asterisks inserted inside the D201 bars indicate statistically signiﬁcant differences between the response at D21 and D201 for each vaccine dose (*p ≤ 0.05, **p ≤ 0.01).
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SCR N40% for all 4 strains.
3.4. T-cell response
3.4.1. QVLP vaccine elicited a polyfunctional and cross-reactive CD4 T cell
response 21 days after immunization
We observed an overall increase in the Ag-speciﬁc CMI between D0
and D21 in vaccinated subjects but not in placebo (data not shown).Detailed T cell responses following ex vivo Ag re-stimulationweremea-
sured in subjects who received 15 μg QVLP per strain and compared to
the placebo group (n= 9 and 6 respectively). At 21 days after vaccina-
tion, there was a striking increase in the proportion of inﬂuenza HA-
speciﬁc polyfunctional CD4 T cells following homologous Ag recall in
the QVLP recipients compared to placebo. This increase was observed
for each of the four strains included in the QVLP (Fig. 6). The
polyfunctional CD4 T cells weremainly IFN-γ+ (Fig. 7A) but the speciﬁc
CD107a/IFN-γ/IL-2/TNF-α signatures varied between strains (Suppl.
Fig. 5. SerumHI antibody response against two heterologous inﬂuenza B strains 21 and 201 days after vaccination with 3 μg, 9 μg and 15 μg of the plant-derived quadrivalent VLP vaccine.
A) GeometricMean titer (GMT), B) percent of seroconversion rate (SPR), C) percent of seroconversion rate (SCR) andD) geometricmean fold increase ratio (GMFR). The dotted linesmark
the values of the CHMP criteria for licensure. The different letters indicate statistically signiﬁcant differences (p ≤ 0.05) between vaccine groups and Placebo at D21 (lower case) and at
D201 (upper case). Asterisks inserted inside the D201 bars indicate statistically signiﬁcant differences between the response at D21 and D201 for each vaccine dose (*p ≤ 0.05,
**p ≤ 0.01). Hash signs indicate statistically signiﬁcant differences between vaccine doses (#p ≤ 0.05, ##p ≤ 0.01) at each time point.
80 S. Pillet et al. / Clinical Immunology 168 (2016) 72–87Fig. 1). No statistically signiﬁcant differences were observed in IFN-γ+
CD4 T cells between QVLP recipients and placebo at D0 (data not
shown). No signiﬁcant CD8 T cell responses were observed against
homologous strain Ag at 21 days after vaccination. Memory cells inthe IFN-γ+ CD4 T cell population elicited by QVLP vaccine were charac-
terized according to the expression of CD45RA, CCR7 and CD27 as
follows: naïve (CD45RA+ CCR7+ CD27+), central memory (CM:
CD45RA− CCR7+ CD27+), transitional memory (TM: CD45RA− CCR7−
Fig. 6. Homologous CD4 T cell-mediated response 21 days after vaccination. Relative distribution of CD4 T cell subsets based on the expression of the IFN-γ, IL-2, TNF-α and CD107a after
ex vivo Ag re-stimulated with homologous Ag. The black arcs highlighted polyfunctional CD4 T cells. The permutation analysis (SPICE software http://exon.niaid.nih.gov/spice) revealed
signiﬁcant (*p ≤ 0.05) differences in the distribution of the functional response between placebo and 15 μg QVLP groups.
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memory CD45RA+ (TEMRA: CD45RA+ CCR7−) CD27− and TEMRA
CD27+ [37,38]. At D21, the HA-speciﬁc IFN-γ+ CD4 T cells were mainly
TEMRA CD27+ (over 50%) and TM (between 20% to 30%), with the
exception of A/H3N2Vic HA-speciﬁc CD4 T cells wherein the relative
proportion of TEMRA CD27− reach ~30% (Fig. 7A, detailed pie-charts).
To assess CMI directed against heterologous HA antigens, PBMCs
were stimulated ex vivo with peptide pools from the B/Mass or A/
H3N2 HK HA proteins. Increases of B/Mass and A/H3N2 HK cross-
reactive CD4 T cells were noticed andwe observed a signiﬁcant increase
of Ag-speciﬁc IFN-γ+ CD4 T cells in the 15 μg QVLP recipients as com-
pared to placebo (Fig. 7B). The frequencies of IFN-γ+ IL-2− TNF-α+
CD107+, IFN-γ+ IL-2+ TNF-α+ CD107− and IFN-γ+ IL-2− TNF-α+
CD107− A/H3N2 HKHA-speciﬁc CD4 T cell populationswas signiﬁcant-
ly higher in vaccinated subjects as compared to placebo (Suppl. Fig. 2,
upper panel). B/Mass cross-reactive CD4 T cells exhibited a similar
pattern although the difference was only signiﬁcant for the IFN-γ+ IL-
2− TNF-α+ CD107− (Suppl. Fig. 2, lower panel). The A/H3N2 HK HA-
speciﬁc IFN-γ+ CD4 T mainly (N75%) displayed a TEMRA CD27−
phenotype (Fig. 7B higher panel, detailed pie-chart) while B/Mass
HA-speciﬁc IFN-γ+ CD4 T cells displayed TEMRA CD27+ and TM pheno-
types (Fig. 7B lower panel, detailed pie-chart).3.4.2. The QVLP vaccine also elicits a long-term polyfunctional and
cross-reactive CD4 T cell response
Six months after immunization, minimal expression of CD107 was
observed on PBMC after ex vivo stimulation (data not shown). The anal-
ysis was therefore focused on the expression of IL-2, TNF-α and IFN-γ
using the same three surfacemarkers to deﬁnememory cell populations
(CD45RA, CCR7 and CD27 as above). Memory CD45RA−CD4 T cells ex-
pressing at least one of these 3 cytokines upon homologous or heterol-
ogous stimulation were mainly TM. The proportion of Ag-speciﬁc CD4
TM cells expressing at least one cytokine (Responsive CD4 TM cells)
was higher in 15 μg QVLP group than in placebo for both homologous
(Fig. 8, left panel) and heterologous (Fig. 9, left panel) Ag although
that difference was only statistically signiﬁcant for A/H3N2 Vic HA-
speciﬁc CD4 TM cells. The functional signatures of TM at 201 days
after immunization are detailed on the right panel of Figs. 8 and 9.
A/H3N2 Vic HA-speciﬁc double positive IFN-γ+ TNF-α+ as well as
single positive IFN-γ+ and TNF-α+ CD4 TM cells were signiﬁcantly
increased in the QVLP group compared to placebo (Fig. 8 right panel).
Similar trends, although not statistically signiﬁcant, were observed with
the other homologous strains. A signiﬁcantly higher proportion of heter-
ologous B/Mass HA-speciﬁc double positive IFN-γ+TNF-α+ was also
observed in the QVLP group compared to placebo (Fig. 9, right panel).
Fig. 7. Homologous (A) and heterologous (B) CD4+ T cell-mediated response 21 days after vaccination. Percentage of CD4 T cells expressing IFN-γ upon Ag ex-vivo re-stimulation
(mean ± SE). The signiﬁcant differences between placebo and 15 μg QVLP groups are represented (p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). The pie-charts detailed the relative distribution of
IFN-γ+CD4+ memory T cell subpopulations based on the expression of surface markers CD45RA, CCR7 and CD27 in the 15 μg QVLP group.
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Although the use of inﬂuenza vaccines has clear health beneﬁts in
most seasons, recent events have highlighted serious limitations of
both current products and manufacturing processes. In this context,
plant-based manufacturing has considerable potential since molecular
techniques are used to target wild-type Ag as soon as sequence data
for a new strain becomes available [26]. As a result, this platform can
bemuchmore nimble than classical approaches based on egg- or tissue
culture-adapted viruses. Herein we report the results of a phase 1–2
dose-escalation trial of a QVLP vaccine that was both well-tolerated
and induced strong and cross-reactive humoral and cellular responses.
Pain at the site of injection was the most common AE reported but
was consistently described as mild-to-moderate and of short duration.
Similarly, systemic solicited reactions such as headache, muscle pain
and fatigue were reported to be mild-to-moderate and transient in na-
ture with equal frequency in the QVLP recipients and placebo groups.
Overall, the reactogenicity of the QVLP vaccine was similar to thereported proﬁles of split-virus QIVs and commercial TIVs [8,9,39,40]. It
was also reassuring that we did not see either worsening or induction
of allergic symptoms following QVLP exposure and there was no evi-
dence of a potentially immunopathologic IgE response to plant-origin
carbohydrate motifs present on the QVLP vaccine. These observations
are consistent with our previous work with monovalent plant-based
VLP vaccines [33].
The HI and MN titers were also consistent with previous studies of
monovalent VLP vaccines bearing HA proteins of either seasonal (H1)
or pandemic (H5) inﬂuenza strains [22,23]. Indeed, at 21 days after im-
munization, the two higher doses of QVLP (9 and 15 μg/strain) readily
met all of the CHMP criteria for licensure for all four strains in the vac-
cine, including HI titer N40 deﬁned as the humoral correlate of protec-
tion. Even the lowest QVLP dose (3 μg/strain) met these criteria for
the inﬂuenza A strains. Despite the relative small sample size of this
phase 1–2 study, these observations demonstrate that the QVLP vaccine
can achieve standard immune correlates of protection at HA doses com-
parable to commercial TIV or QIV vaccines in healthy adults. The
Fig. 8. Long-term homologous CD4+ T cell-mediated responses 201 days after vaccination. Left panel: Percentages of transitional memory (TM, CD45RA−CCR7−CD27+) CD4 T cells
expressing at least one of the three functional markers (IL-2, TNF-α or IFN-γ) upon ex vivo Ag-speciﬁc re-stimulation (mean ± SE). Right panel: Qualitative analysis of the TM CD4 T
cell response based on the expression of the three functional markers. The mean (bar ± SE) and individual results (dots) are represented for the seven functional signatures. The
symbol * indicates signiﬁcant differences between placebo and 15 μg QVLP groups (p ≤ 0.05).
83S. Pillet et al. / Clinical Immunology 168 (2016) 72–87functional nature of the Abs induced by QVLP vaccination was con-
ﬁrmed by the MN results that correlated well overall with HI titers. Al-
though occasional discrepancies between HI and MN results have
been reported and there is some evidence that MN results may be
more sensitive predictors of protection for children [41], our data sug-
gest that the Abs induced in the ﬁrst 3 weeks after QVLP vaccination
are capable of both inhibiting hemagglutination and preventing viral
entry into host cells (neutralization).
Durability of the sero-response is another important consideration
for novel inﬂuenza vaccines. Although at least one commercial TIV hasbeen reported to increase the number of inﬂuenza virus-speciﬁc mem-
ory B cells [42], there is a great deal of evidence that TIV/QIV-induced
antibodies fall rapidly over time with some studies showing slightly
greater persistence of antibodies directed against either A [43,44] or B
strains [40]. In our study, GMT were maintained at ≥1:40 for the 4
strains included in QVLP for at least 6 months in the 15 μg group. At
all QVLP doses, antibody persistence was generally greater for inﬂuenza
A than the B strains. The mechanisms that underlie this long-lasting re-
sponse following QVLP vaccination are not yet fully understood but
may, in part, be attributable to the parallel induction of CD4 T cell help
Fig. 9. Long-term heterologous cell-mediated responses 201 days after vaccination Left panel: Percentages of transitional memory (TM, CD45RA−CCR7−CD27+) CD4 T cells expressing at
least one of the three functionalmarkers (IL-2, TNF-α or IFN-γ) upon ex vivo Ag-speciﬁc re-stimulation (mean± SE). Right panel: Qualitative analysis of the TMCD4 T cell response based
on the expression of the three functionalmarkers. Themean (bar± SE) and individual results (dots) are represented for the seven functional signatures. The symbol * indicates signiﬁcant
differences between placebo and 15 μg QVLP groups (p ≤ 0.05).
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creased sero-response have been reported in subjects who have been
previously vaccinated [46,47]. We do not yet know how the unusual
persistence of the antibodies induced by QVLP vaccination may inﬂu-
ence subsequent immunizations and/or exposure to natural disease.
Since antigenic drift strains often occur during and between inﬂuenza
seasons, cross-reactivity is another important consideration for any in-
ﬂuenza vaccine. Although sera were not tested against a larger panel
of heterologous antigens, the QVLP vaccine at higher doses (9 and
15 μg/strain) induced strong cross-reactive antibody responses against
the B/Mass and A/H3N2 Uru strains at least. Lower levels of cross-
reactive antibodies were induced against the A/H1N1 Bris and B/Mal
strains. The A/H1N1 Bris results may be partially explained by the low
HA sequence homology between A/H1N1 Cal and A/H1N1 Bris and
H1/Bris (79.2%) compared to the H3 (97.3%) and B/Victoria antigens
tested (99%). On the other hand, the B Yamagata HA antigens included
in this study share 98.8% homology yet there was little evidence of
cross-reactivity for B/Mal. Differences in HA glycosylation may also
have contributed to the low cross-reactivity observed for the A/H1N1
Bris and B/Mal strains. The A/H1N1 Bris HA has two additional glycosyl-
ation sites at positions 122 and 157, both of which lie within the highly
immunogenic receptor binding domain (RBD) [48]. The presence of
additional glycans in this critical region could certainly interfere with
binding of anti-HA Abs induced by the HA of A/H1N1Cal included in
the QVLP [49–51]. Poor cross-reactivity for the heterologous B/Mal
strainmay be also have been inﬂuenced by the presence of an additional
N-linked glycan site at position 197 that commonly occurs in egg-
adapted B/Victoria-lineage viruses including the B/Bris strain included
in the QVLP vaccine.
Given that HI titers have long been the major criteria for inﬂuenza
vaccine licensure, it is not surprising that most commercially available
inﬂuenza vaccines (e.g.: TIV/QIV) have been designed to induce strong
humoral responses. However, protective responses for most viralillnesses result from a strong collaboration between the different ele-
ments of the immune system: innate and adaptive, humoral and cellular
[52,53]. Indeed, while pre-formed antibodies can provide protection
frommany viral illnesses (i.e.: antibodies can be sufﬁcient), CMI is gen-
erally required to effectively clear most viral infections and to maintain
long-term immunity. Actually, there is a growing consensus that CMI,
and CD4 T cell responses in particular [54], play a key role in long-
term, cross-protective immunity to inﬂuenza. Such responses may be
critically important in the elderly [55]. With the exception of the live-
attenuated formulation (LAIV) commercial inﬂuenza vaccines are gen-
erally very poor inducers of robust anti-viral CMI [56–58]. It is notewor-
thy that, despite generally lower detectable serum antibody levels, LAIV
also provides better cross-protection than inactivated TIV/QIV formula-
tions [57]. Despite the non-living nature of plant-based VLPs and the
fact that inﬂuenza HAs are generally not considered to be strong in-
ducers of CMI, monovalent inﬂuenza VLP vaccines bearing either H1
or H5 have consistently elicited strong cellular responses in both animal
models [23] and humans [22]. In the current study, these results have
been conﬁrmed and extended through a detailed characterization of
both the short- and long-term cellular responses induced by QVLP in
healthy adults.
Compare to the placebo recipients, the QVLP-immunized subjects
mounted striking HA-speciﬁc poly-functional CD4 T cell responses at
D21 that were still readily detected at D201. Poly-functionality has
been associated with better protection against many infections includ-
ing inﬂuenza [59–61]. CD4 T cells play diverse roles in response to infec-
tion. CD4 T cells provide necessary help for both CD8 T cells and B cells
to achieve their full functional potential, as well as mediating direct ef-
fector functions through cytolysis of inﬂuenza-infected cells [62,63].
Most of the poly-functional CD4 T cells in the QVLP vaccinated subjects
were IFN-γ+, a widely-used parameter to assess effective anti-viral re-
sponses. In the context of inﬂuenza vaccination, it is particular interest-
ing that such IFN-γ+ CD4 T cells are an approved correlate of protection
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since this cytokine has an important role in the clearance of a wide
range of viral, bacterial, parasitic and fungal infections [61]. In addition,
the expression of IFN-γ in T cells has been associated with homing abil-
ity to lungs [65] and the presence of tissue-resident memory T cells in
lungs has been associated with better protection against inﬂuenza [66,
67]. IFN-γ produced by CD4 T cells is thought to be necessary for the
generation of lung-resident CD103+ CD8 tissue-resident memory T
cells that provide enhanced protection against infection at mucosal
sites [68]. Furthermore, Wilkinson et al. [69] showed that pre-existing
inﬂuenza-speciﬁc IFN-γ+ CD4 T cell correlate with disease protection
in humans. Inﬂuenza Ag-speciﬁc CD4+ T cells also likely play an impor-
tant role in mediating cross-reactive protection after immunization and
natural disease [18,70].
The Ag-speciﬁc IFN-γ+ CD4 T cells elicited by the QVLP vaccine
21 days after immunization were essentially memory cells, either TM
or TEMRA. CCR7− effector memory cells were associatedwith better pro-
tection and have been proposed as one of the most desirable popula-
tions to be elicited by a vaccine [71]. Concurrently with the expression
of IFN-γ, the presence of CD27 is also strongly correlatedwith the ability
of T cells to home to the lungs [72] and Ag-speciﬁc T cells in the lungs of
mice that survive inﬂuenza lethal challenge strongly express CD27 [73].
At D201, the HA-speciﬁc CD4 memory T cells detected in peripheral
blood after vaccination with QVLP were mostly phenotyped as TM
cells. These cells display an intermediary phenotype between CM and
EM, having a longer lifespan than EM cells while maintaining the capac-
ity to quickly differentiate into effector cells that can control virus repli-
cation. Although we have previously observed a limited CD8+ T cell
response following monovalent H1-VLP immunization [22] and saw
hints of such a response in the QVLP recipients, we acknowledge that
the timing of sample collection in the current study as wells as the use
of VLP for ex vivo stimulation was not optimal for the identiﬁcation of
cytotoxic T cell (CTL) responses.
In conclusion, this ﬁrst, dose-escalation clinical trial of a plant-made
QVLP vaccine has demonstrated that a single, unadjuvanted dose of this
candidate vaccine was well-tolerated and elicited strong and cross-
reactive humoral and cellular responses that persisted for at least
6 months. At the higher doses (9 and 15 μg/strain), QVLP vaccine
met all of the CMHP criteria for licensure. Unlike most other non-
living inﬂuenza vaccines, QVLP vaccine also induced a striking poly-
functional and cross-reactive CD4 T cell memory response.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.clim.2016.03.008.
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